What is the next therapeutic step for a patient with type 2 diabetes who is on sitagliptin and metformin 1 g twice daily but has not achieved glycemic targets?

Add a GLP-1 Receptor Agonist to Your Current Regimen

The next step is to add a GLP-1 receptor agonist (GLP-1 RA) to your metformin and sitagliptin regimen. This recommendation is based on the most recent 2025 ADA guidelines, which prioritize GLP-1 RAs as the preferred injectable therapy when oral agents fail to achieve glycemic targets 1.

Why GLP-1 RA is the Best Choice

The 2023 ADA Standards explicitly state that GLP-1 RAs should be considered as the preferred option for individuals requiring injectable therapy for glucose control 2. When comparing GLP-1 RAs to insulin in patients needing additional glucose lowering, GLP-1 RAs demonstrated:

• Similar or superior glycemic efficacy compared to basal insulin
• Lower risk of hypoglycemia than insulin
• Beneficial effects on body weight (weight loss vs. weight gain with insulin)
• Fewer gastrointestinal side effects than expected 2

The Treatment Algorithm

Based on the 2025 ADA guidelines 1, here's your specific pathway:

1. Continue metformin (you're already on 1g twice daily - this is appropriate)
2. Continue sitagliptin (DPP-4 inhibitor - can be maintained)
3. Add a GLP-1 RA - this addresses the inadequate glycemic control

Important Contraindications to Check

Before starting a GLP-1 RA, ensure the patient has:

• No personal or family history of medullary thyroid carcinoma
• No history of multiple endocrine neoplasia type 2 3

Why Not Other Options?

Why Not Just Add Insulin?

While insulin is effective, the 2023 guidelines clearly state that GLP-1 RAs are the preferred injectable therapy before moving to insulin 2. Insulin should be reserved for:

• Severe hyperglycemia (blood glucose ≥300 mg/dL or A1C ≥10%)
• Presence of catabolic symptoms (weight loss, ketosis)
• When GLP-1 RAs are contraindicated or have failed 1

Why Not Add Another Oral Agent?

You're already on dual oral therapy (metformin + sitagliptin). The 2020 ADA guidelines note that most oral medications rarely exceed 1% A1C reduction 4. Adding a third oral agent would likely provide insufficient glycemic improvement compared to a GLP-1 RA.

What About SGLT2 Inhibitors?

While SGLT2 inhibitors are excellent agents, particularly for patients with cardiovascular disease or chronic kidney disease, the guidelines prioritize GLP-1 RAs when injectable therapy is needed for glycemic control 2, 1. SGLT2 inhibitors could be considered if:

• The patient has established cardiovascular disease
• The patient has chronic kidney disease
• GLP-1 RAs are contraindicated

Practical Implementation

Initiation:

• Start with an appropriate starting dose for the selected GLP-1 RA (varies by agent - semaglutide, dulaglutide, liraglutide, etc.)
• Consider patient preference regarding injection frequency (weekly vs. daily formulations)
• An oral formulation (oral semaglutide) is available if the patient prefers 2

Titration:

• Titrate to maintenance dose according to the specific agent's protocol
• Reassess glycemic control every 3-6 months 1

If Still Above Target After GLP-1 RA: Only then should you add basal insulin to the regimen 1. Start with 10 units daily or 0.1-0.2 units/kg/day, and titrate based on fasting plasma glucose targets 1.

Common Pitfalls to Avoid

1. Therapeutic inertia: Don't delay adding the GLP-1 RA. The guidelines emphasize avoiding therapeutic inertia and reassessing treatment every 3-6 months 1

2. Jumping straight to insulin: Unless there are severe symptoms or very high glucose levels, GLP-1 RAs should be tried first 2

3. Stopping metformin: Continue metformin as the foundation therapy unless contraindicated 1

4. Ignoring cardiovascular risk factors: If the patient has established cardiovascular disease or high cardiovascular risk, this further supports the use of GLP-1 RAs, as certain agents (liraglutide, semaglutide, dulaglutide) have demonstrated cardiovascular benefits 4

The evidence strongly supports that triple therapy with metformin + DPP-4 inhibitor + GLP-1 RA provides superior glycemic control compared to dual combinations, with a recent 2023 study showing significantly greater A1C reduction (-1.73% vs -1.28% with dual therapy) 5.